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Radioembolization has certainly come a long way since its early years of development in Australia
and Asia, where the incidence andmortality rates of hepatic malignancies remain among the highest
globally (1). Now, a necessary arsenal component of cancer centers worldwide, it has evolved
from its original indication for liver tumors, and has shown utility for tumors in other organs
as well.
In the purest sense, radioembolization has enabled interventional radiologists to use beta emis-
sions to radiate malignancies refractory to conventional treatments. It has, however, also led to
the challenging dilemma of figuring out how to make sure lesions are adequately radiated while
maintaining the requisite safety profile. Achieving the utopian combination of highest possible dose
to tumor and lowest possible dose to unaffected tissue has beenmore complex than initially thought.
We now know that standard scintigraphic imaging is unable to provide reliable quantitative dosime-
try estimates. Furthermore, we have learned through years of practice that tissue and tumor radiation
thresholds vary with certain clinical and histologic parameters. Coupled with recent advances in
positron emission tomography (PET) imaging, these findings have brought radioembolization right
to the doorstep of personalized medicine.
This research topic puts together a collection of papers which, when taken together, bring
a personalized approach to radioembolization within arm’s reach of multidisciplinary treatment
centers. The author list is illustrative of the synergy among experts in different fields, which
is required for treatment to be successful – including Oncology, Diagnostic and Interventional
Radiology, Nuclear Medicine and Medical Physics. As an editor, I am particularly proud to note the
fact that this project represents a truly international effort, with authors and reviewers representing
centers which have been blazing trails in radioembolization in Asia, Europe, Australia, and the
Americas.
Two articles lay the groundwork with an overview of radioembolization as applied to malig-
nancies. One is dedicated to hepatic metastases from colorectal primary malignancies (2) and the
other looks at publications on radioembolization of both extrahepatic tumors and hepatic tumors of
non-colorectal or hepatocellular primary origin (3).
A detailed review of data and outcomes that state the case for radioembolization’s role
beyond palliation, as a tool enabling definitive hepatic resection or successful transplantation, is
provided (4).
Marta Cremonesi and her Italy-based medical physicist colleagues have contributed a critical
review of radioembolization from a radiobiologic and dosimetric perspective (5). Significantly, the
authors discuss the scientific basis for a paradigm shift to individualized approaches to dosimetry
and risk stratification. This is ideally read in tandem with a review article on the side effects of 90Y
radioembolization (6), and followed by an article describing the use of hepatobiliary scintigraphy as
a tool for imaging regional liver function following radioembolization (7).
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The rapid growth of PET/CT as a mainstream imaging
modality has positioned it well for a routine role in post-
radioembolization imaging, with many suggesting it should
replace scintigraphy as the next gold standard. This has made
radioembolization a wide open field for PET research. It is,
therefore, no coincidence that four articles in this collection are
rooted in utilization of PET/CT imaging in conjunction with
radioembolization.
Pasciak et al. have provided a must read article on the role
of PET/CT in tandem with radioembolization, beginning with
a concise review of the physics of 90Y positron emission, fol-
lowed by a review of the clinical utility of the modality and
the promise it holds for improving radioembolization outcomes
(8). Anyone engaged in research in the field will find a valuable
signpost in the author’s suggestions for improving 90Y PET/CT
imaging.
Those interested in seeing PET/CT at work following radioem-
bolization are certain to appreciate images from actual cases.
These are included together with a description of an image
assessment technique for detection of non-target deposition of
90Ymicrospheres using PET/CT following radioembolization (9).
Two prospective research papers are included, which are sure to
be references for future PET/CT dosimetry initiatives: one com-
pares techniques for 90Y PET/CT Image-Based Dosimetry Fol-
lowing Radioembolization (10), and the other describes a method
for determination of radiation dose to both tumor and unaffected
liver tissue using PET following 90Y radioembolization (11).
Completing the loop, lest we fail to appreciate the value that
scintigraphy brings to radioembolization, is a contribution by
Walrand et al. Their article provides an early indication of how
simulations can advance planar imaging, and keep hopes alive for
the ability to perform dosimetry assessments without needing to
move patients off the catheterization table (12).
If this research topic is any indication, the once seemingly
cookie cutter approach to radioembolization is now a thing of the
past. Instead, radioembolization will soon be to me as a suit is to
a tailor and a meal is to a chef: uniquely adapted to the patient,
every step of the way.
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